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Background: Previous studies have suggested a role played by respiratory viruses in the exacerbation of cystic fibrosis (CF). However, the impact
of respiratory viruses could have been underestimated because of the low detection rate by conventional laboratory methods.
Methods: Children with CF had nasal swabs and sputum samples obtained on a routine basis and when they developed respiratory exacerbations.
Nucleic Acid Sequence Based Amplification (NASBA) was used to detect respiratory viruses from nasal swabs. The definition of a respiratory
exacerbation was when the symptom score totalled to 4 or more, or if the peak expiratory flow fell by more than 50 l/min from the child's usual
best value, or if the parent subjectively felt that the child was developing a cold.
Results: 71 patients had 165 reported episodes of respiratory exacerbations. 138 exacerbation samples were obtained of which 63 (46%) were
positive for respiratory viruses. In contrast, 23 of 136 asymptomatic nasal swabs (16.9%) were positive for respiratory viruses. There was
significantly more viruses being detected during respiratory exacerbations, in particular influenza A, influenza B and rhinovirus (pb0.05).
Upper respiratory symptoms significantly correlated with positive respiratory viral detection (pb0.05). This study also showed that viral
respiratory exacerbations in CF could be independent from bacterial infections.
Conclusions: Respiratory viruses are associated with exacerbations in CF and upper respiratory symptoms are strong predictors for their presence.
‘Real-time’ NASBA has a rapid turn-around time and has the potential to aid clinical decision making, such as the use of anti-virals and
administration of antibiotics.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Influenza vaccination; Cystic fibrosis; NASBA1. Introduction
Life expectancy for Cystic Fibrosis (CF) patients has
increased dramatically over the last 40 years [1]. However,
progressive pulmonary damage with eventual respiratory failure
is still the major cause of morbidity and mortality in CF [2] and
bacterial infection is generally thought to be the major cause of⁎ Corresponding author. 146 Adventurers Quay, Cardiff Bay, Cardiff, CF10
4NR, Tel.: +44 2920465384; fax: +44 2920465384.
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doi:10.1016/j.jcf.2007.12.002clinical deterioration [3]. Recently, evidence from literature
shows that respiratory viruses lead to pulmonary exacerbation
and disease progression [4–7] and an increase in bacterial
adherence to the CF airways [8,9] from in vitro studies. This
results in prolonged hospitalizations [10] of CF patients infected
by viruses but their true impact on CF may yet have been
underestimated by previous studies for a number of reasons:
Firstly, respiratory viruses may trigger bacterial infections [11–
13] and so the presence of bacteria does not necessarily exclude
viral infections. Secondly, many previous studies used tissue
culture and immunofluorescence techniques which are relativelyd by Elsevier B.V. All rights reserved.
Table 1
Sequences for primers and molecular beacons
Virus Primer identification
nuceotide no.
Sequence 5′→ 3′ Function
HPIV1 P1: 55 CGATGGCTGAAAAAGGGA RT reverse primer
P1: 139 CACCAGCAGGAAGGACACA RT-PCR reverse primer
P1: 857 GGCAAGGAGCATAACTGATAA RT-PCR forward primer
P1: 549 AATTCTAATACGACTCACTATAGGGAGAAGGGAACCCCTACTGAGCAACAAC NASBA P1 primer T7 RNA
polymerase tail
P1: 801 GATGCAAGGTCGCATATGAGCCTGTTGTCGTTGATGTCATA NASBA P2 primer ECL detection tail
PR1: 669 CTTCCCTATATCTGCACATCC HPIV1 capture probe
HPIV1MB CCATGCGCTTCCCTATATCTGCACATCCCGCATGGT HPIV1 molecular beacon
HPIV2 P2: 309 CACAGCAAGGCATTATTCA RT reverse primer
P2: 738 CAATGGGGATAATACAACAAT RT-PCR reverse primer
P2: 1371 ATGCAGACCACCAAGAGG RT-PCR forward primer
P2: 848 AATTCTAATACGACTCACTATAGGGAGAAGGCCAGGAGGTTGTGTCTTGTAT NASBA P1 primer T7 RNA
polymerase tail
P2: 1058 GATGCAAGGTCGCATATGAGGAGACCACCATATACAGGAAA NASBA P2 primer ECL
detection tail
PR2: 979 CCCTGTTGTATTTGGAAGAGA HPIV2 capture probe
HPIV2 MB CCAAGCCCCTGTTGTATTTGGAAGAGAGCTTGG HPIV2 molecular beacon
HPIV3 P3: 770 ATAACTGTAAACTCAGACTTGGT RT reverse primer
P3: 896 ACTCCCAAAGTTGATGAAAGA RT-PCR reverse primer
P3: 1548 GACAGATGACACAATGCTCC RT-PCR forward ptimer
P3: 1052 AATTCTAATACGACTCACTATAGGGAGAAGGGGACCAGGGATATACTAYAAA NASBA P1 primer T7 RNA
polymerase tail
P3: 1201 GATGCAAGGTCGCATATGAGTTGACCATCCTYCTRTCTGAA NASBA P2 primer ECL detection tail
PR3: 1129 CACCCAGTTGTRTTGCAGATT HPIV3 capture probe
HPIV3MB CCATGCGCACCCAGTTGTRTTGCAGATTCGCATGGT HPIV3 molecular beacon
HPIV4A and
HPIV4B
P4: 359 GCTTATGGGATCAGACACACA RT reverse primer
P4: 531 GAAAGAGGCTTGGGTTACACA RT-PCR reverse primer
P4: 1147 GCTCTTATCACAGTCTCCAAA RT-PCR forward primer
P4: 910 AATTCTAATACGACTCACTATAGGGAGAAGGCCTGGAGTCCCATCAAAAGTA NASBA P1 primer T7 RNA
polymerase tail
P4: 1088 GATGCAAGGTCGCATATGAGCATCTATACGAACACCTGCTC NASBA P2 primer ECL
detection tail
PR4: 1045 GGTTCCAGAYAAWATGGGTCT HPIV4 capture probe
HPIV4 MB CCAAGCGGTTCCAGAYAAWATGGGTCTGCTTGG HPIV4 molecular beacon
229E 229E : 1949 TAAGGCGTCTTCAATAGT RT reverse primer
229E : 1872 CATAAGTGGAGCAATCAA RT-PCR reverse primer
229E : 1281 TTGTATGTTTCTTGGAGT RT-PCR forward primer
229E : 1658 AATTCTAATACGACTCACTATAGGGAGAAGGAGTGCCATTGGACGCATAGAA NASBA P1 primer T7 RNA
polymerase tail
229E : 1391 GATGCAAGGTCGCATATGAGTTATGATGTATCTGGTGTGGG NASBA P2 primer ECL
detection tail
PR229E ACCATCTACTCTATCACTCCT 229E capture probe
229E MB CCATGCACCATCTACTCTATCACTCCTGCATGGT 229E molecular beacon
RSVA and B RSV RT GATCAAAAGTGCTCTACTAT RT reverse primer
RSV RT+ GATCAAAAGTGCTCTACTAT RT-PCR reverse primer
RSV RT- AGTTTTGCCATAGCATGACA RT-PCR forward primer
RSV T7 A+B AATTCTAATACGACTCACTATAGGGGAYAGAGGATGGTAYTGTGA NASBA P1 primer T7 RNA
polymerase tail
RSV ECL (A) GATGCAAGGTCGCATATGAGCAATGGCTCCTAGAGATGTGA NASBA P2 primer ECL
detection tail
RSV ECL (B) GATGCAAGGTCGCATATGAGCTATAGCTCCAAGAGAAGTAA NASBA P2 primer ECL
detection tail
RSVA+B BIO CDGAGCTGCTTAYRTCTGTTT RSVA and B capture probe
RSV MB A+B CCATGCCDGAGCTGCTTAYRTCTGTTTGCATGG RSVA and B molecular beacon
Influenza A Flu A RT AGCAGGGTAGATAATCACTC RT reverse primer
Flu A RT+ AGCAGGGTAGATAATCACTC RT-PCR reverse primer
Flu A RT− TTGTGCHGCTGTTTGRAATT RT-PCR forward primer
Flu A T7 AATTCTAATACGACTCACTATAGGGAGCAGGGTAGATAATCACTC NASBA P1 primer T7 RNA
polymerase tail
Flu A ECL GATGCAAGGTCGCATATGAGATYTCRKTDGCATTCTGGCG NASBA P2 primer ECL
detection tail
Flu A Bio TAAGAYCGTTTGGTGCCTTG Influenza A capture probe
Flu A MB CCAAGCTAAGAYCGTTTGGTGCCTTGGCTTGG Influenza A molecular beacon
(continued on next page)
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Table 1 (continued)
Virus Primer identification
nuceotide no.
Sequence 5′→ 3′ Function
Influenza B Flu B RT pol ACACAATGGCAGAATTTAGTG RT reverse primer
Flu B RT+ ATCCTGAAYTACARCCAGCA RT-PCR reverse primer
Flu B RT− AGGTCCYCCCATTTCAACTT RT-PCR forward primer
Flu B pol T7 AATTCTAATACGACTCACTATAGGGAGAAGGCTATTCAACATCTGCGTCCATC NASBA P1 primer T7 RNA
polymerase tail
Flu B pol ECL GATGCAAGGTCGCATATGAGATYACTTCATAYTGTGGTCTCA NASBA P2 primer ECL detection tail
Flu B pol Bio CCTTGTCCTTCTAATGCTGTAT Influenza B capture probe
Flu B pol MB CCAAGCCCTTGTCCTTCTAATGCTGTATAGCTTGG Influenza B molecular beacon
HRV HRVJ P1 AATTCTAATACGACTCACTATAGGGAGACCAMYWTTYTGYSTWGAWAC NASBA P1 primer T7 RNA
polymerase tail
HRVJ P2 GATGCAAGGTCGCATATGAGCTCCGGCCCCTGAATGYGGCT NASBA P2 primer ECL detection tail
HRVJ Pro GAYGGGACCRACTACTTTGG HRV capture probe
HRVJMB-FAM CCAAGCGAYGGGACCRACTACTTTGGGCTTGG HRV molecular beacon FAM
HRV X PR1 CGCGCAAGTCCGTGGCGGAA HRV cross primer 1
HRV X PR2 TGGGYAACTCTGCAGCGGAA HRV cross primer 2
HRV X PR3 CGGGCAACTCTGCAGCGGAA HRV cross primer 3
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techniques used in most published studies in CF [6,7,11,14].
Thirdly, few studies have used sensitive methods such as
molecular based technique for viral detection [12,15–17].
Finally, many previous studies were poorly designed with a
small study sample and used invalidated criteria to define
pulmonary exacerbations, therefore providing biased results.
Identifying respiratory viruses in CF is important in clinical
decision making and is potentially important as new anti-virals
are becoming readily available [18].
1.1. Aims
1. To investigate the incidence of respiratory viruses in a CF
paediatric population during pulmonary exacerbations and
routine (asymptomatic) settings.
2. To investigate if upper respiratory tract symptoms are
associated with viral infections.
3. To investigate if bacterial infection is associated with viral
infection.
2. Materials and methods
2.1. Patients
This was a prospective study conducted for 17 months
between December 2002 and May 2004 involving patients with
CF below the age of 18 years from four CF centres, namely
University Hospital of Wales in Cardiff, Royal Gwent Hospital
in Newport, and Singleton Hospital in Swansea and Neville
Hall Hospital in Abergavenney.
2.2. Sample collection
Nasal swabs were obtained from the patients whenever they
developed symptoms suggestive of respiratory exacerbations and
whenever they attended for routine outpatient assessment on a 2
monthly basis. Each nasal swabwas obtained by inserting a sterile
cotton swab into one of the nostrils to a depth of 2 to 3 cm. Theswab was then subjected into 0.5 ml of guanidium thiocyanate
lysis buffer. It was transported with ice packs to the laboratory and
then stored at −80 °C until undergoing nucleic acid extraction on
a later date. A paired sputum/cough swab sample was also
obtained at the same time for bacteriology and was analysed by
the National Public Health Service (NPHS) of Wales.
2.3. Virus identification
Respiratory virus nucleic acid materials were extracted from
the nasal swabs using silica slurry as described by Boom et al.
[19]. Extracted materials were amplified at ‘real-time’ using
Nucleic Acid Sequence Based Amplification (NASBA) in
conjunction with molecular beacons [20–23]. The panel of
respiratory viruses studied included influenza A, influenza B,
respiratory syncytial virus (RSV), parainfluenza viruses (PIV)
types 1 to 4, rhinovirus and coronavirus. The sequences of
primers and molecular beacons used in ‘real-time’ NASBA
assays are shown in Table 1. Analysis of results was undertaken
using the NucliSens® Easy Q Analyser (BioMérieux Ltd)
isothermically at 41 °C and results were available within
120 min. The NASBA assays have been found to be highly
sensitive with the Tissue Culture Infective Dose being between
1 to 1 in 10−5 virus input (TCID50) and 100 to 0.1 copies of
synthetic RNA. The assays are also specific with no background
signal detected with a cross-reacting panel including a range of
respiratory viruses and a lysis buffer negative control. The cut-
off threshold for a positive result was defined as 20% above the
negative control wild-type signal [22].
2.4. Bacterial isolation
Bacterial isolation in this study was performed by the NPHS
of Wales and the methods were based on the ‘Antibiotic
treatment for CF’ published in the CF Trust Report in 2002
(www.cftrust.org.uk) and the standard operating procedures
(BSOP 57) from the ‘National Standard Procedure on the
Investigation of Bronchoalveolar Lavage, Sputum and Asso-
ciated Specimens’ issued by the Standards Unit, Evaluations
Table 2
Demographics of patients who enrolled in the study and those who declined to
join
Patients enrolled in
study (n=71)
Patients who declined to join
the study (n=80)
Median age in years
(range)
9 (0–18) 7 (0–18)
M:F ratio 2.9:1 1.2:1
% of F508
homozygous⁎⁎
46 50
% of F508
heterozygotes⁎⁎⁎
49 41
% of FEV1N80% 69
# 70##
% of Pseudomonas
colonization
21 18
% of Staph
colonisation
10 15
⁎⁎denotes percentage of delta F508 homozygous in Caucasian population only.
⁎⁎⁎denotes percentage of delta F508 heterozygote in Caucasian population only.
#51 patients out of 71 in the SNOT population were greater than 5 years of age
who were able to perform lung function.
## 40 out of 80 patients who declined to join the study were greater than 5 years
of age who were able to perform lung function test.
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ogy Division (www.hpa.org.uk).
2.5. Definition of an exacerbation
In this study, each patient (and parents) had been provided with
a symptom diary card which comprised of upper and lower
respiratory symptoms including runny nose, blocked nose, sore
throat, hoarse voice, fever/shivering, cough (daytime and night-
time), wheeze (daytime and night-time), shortness of breath and
school absenteeism [24]. Patients and parents had been asked to
score their symptoms using the diary card regularly. The
symptoms were scored as 0 for no symptoms, 1 for mild
symptoms, 2 for moderate symptoms and 3 for severe symptoms
for each criterion. Each patient above the age of 5 years was also
provided with a mini-Wright Peak Flow Meter and was asked to
record their best of three readings everymorning and evening. The
definition of a respiratory exacerbation was when the symptom
score totalled to 4 or more, or if peak expiratory flow fell by more
than 50 l/min from the child's usual best value, or if the parent
subjectively felt that the child was developing a cold [25]. Under
these circumstances, the parents or patients were encouraged to
contact the investigators to have a nasal swab taken.
Patients and parents were reminded regularly throughout the
study by telephone and by letters to contact the investigators in
the event of a respiratory exacerbation and to record their peak
expiratory flows and symptom scores.
2.6. Ethics
The study protocol was approved by the Committee of Ethics
of each individual hospital and research funding was granted by
the Welsh Office of Research and Development (WORD).
Informed consent was obtained from at least one parent at the
beginning of the study and children and parents information
sheets were also provided for clarity.
2.7. Statistics
The statistical analysis of this study was performed using the
software package GraphPad InStat Version 3.0 for Windows
(GraphPad software, San Diego, CA) and the author, FC. Chi-
square test and Fisher's exact test were used to compare the
incidence of respiratory viral infections between routine and
exacerbation samples. Fisher's exact test was also used to compare
the reasons used to define respiratory exacerbations between the
virus positive and virus negative groups. Chi-square test was again
used to study the correlation between respiratory viruses and
bacteria. P-value of b0.05 was taken to be statistically significant.
3. Results
3.1. Patient demographics
There were 151 patients with CF under the care of these four
centres who were all invited to participate in the study. Of these
151 patients, 71 (and parents) kindly agreed to enrol. There wasa male predominance, in total, 53 boys (74.6%) and 18 girls
(25.4%) participated with a median age of 9 years. 46% of the
study population were homozygous for delta F508 and 49%
were heterozygotes for this genetic mutation. 69% had an FEV1
predicted of greater than 80%. 21% and 10% of the study
population were colonised with Pseudomonas aeruginosa and
Staphylococcus aureus, respectively (Table 2). The demo-
graphics of those who did not participate in this study (n=71)
were similar to those who joined the study.
3.2. Prevalence of respiratory viruses
There were 165 reported cases of respiratory exacerbations
from 71 volunteers over the 17 month study period. The
maximum number of reports was 8 from one child. 138 samples
were obtained from 165 reported exacerbation cases. The
discrepancies in numbers arose when 4 volunteers refused nasal
swabs to be taken; 4 were not at home to have samples collected
and 2 were asleep at the point of sample collection. 17 samples
were missed. The median number of samples taken from each
patient was 2 with a range between 0 and 8. Respiratory viruses
were detected by ‘real-time’ NASBA in 63 of 138 cases (46%);
in six cases (4.3%) two viruses were detected, and in three cases
(2.2%) three were detected (Table 3). Influenza A, influenza B,
PIV 4 and rhinovirus were the major viruses detected.
272 routine samples were collected from the patients. The
median number of routine sample collected from each patient
was 4 with a range between 2 and 6. Alternative routine sample
was analysed in this study due to the financial constraint. There
were 23 (16.9%) samples positive for respiratory viruses from
136 routine collections (Table 3). PIV 4 and rhinovirus were the
major viruses detected.
There were significantly more respiratory viruses de-
tected from exacerbation samples than from routine samples
(p-value=0.001). In particular, there were significantly more
Table 3
Respiratory viral detection in different sample types
Virus Number detected (%) p-value⁎ Odds
ratio
Routine,
n=136
Exacerbation,
n=138
FLU A 2 (1.5%) 11 (8.0%) 0.011 0.1723
RSV 3 (2.2%) 4 (2.9%) 1.000 0.7556
PIV 1 1 (0.7%) 2 (1.4%) 1.000 0.5037
PIV 2 2 (1.5%) 1 (0.7%) 0.621 2.015
PIV 3 0 (0.0%) 1 (0.7%) 1.000 0.3358
PIV 4 5 (3.7%) 11 (8.0%) 0.130 0.4407
FLU B 0 (0.0%) 10 (7.2%) 0.002 0.045
Rhinovirus 10 (7.4%) 22 (15.9%) 0.027 0.4185
Coronavirus 2 (1.5%) 1 (0.7%) 0.621 2.015
Any 24 (17.6%) 50 (36.2%) 0.001
Total 25 63
Collected 136 138
Detection rate 18.3% 46%
(“Any” in the table refers to the number of samples that contained one or more
virus of any type.) ⁎p-values are for Chi-squared tests in the case of FLU A,
PIV4, RHINO and ANY and Fisher's exact test for all other variables, since
expected counts were low.
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(p=0.0027) detectable from exacerbation samples (Table 3)
Influenza A was detected in eleven exacerbation samples and
only on two occasions from routine samples (p=0.011).
Similarly, influenza B was detectable from eleven exacerbation
samples compared to none from routine samples (p=0.002).
Rhinoviruses were also more commonly found in exacerbation
samples (p=0.027). PIV 4 was isolated from nasal specimens
on 16 occasions, with 11 from exacerbation and 5 from routine
samples. The difference between the two sample types was not
significant (p=0.13).
3.3. The association of upper respiratory tract symptoms and
viral infections
Of the 138 episodes of respiratory exacerbations, the
summated symptom score was used on 92 occasions (67%) to
define respiratory exacerbations; peak flow fall by greater than
50 l/min from usual best was used on 25 occasions (18%) and
subjective evaluation was used on 21 occasions (15%) to define
the other episodes of respiratory exacerbations.
When the exacerbation nasal swab samples were divided into
virus positive group (where at least one virus was identified
from a nasal swab, [n=50, 36%])and virus negative group
([n=88, 64%], where no virus was identified from a nasal
swab), there were significantly more patients in the virus
positive group using the summated symptom score to define
exacerbations; 39 of 50 episodes (78%) of exacerbations in the
virus positive group in comparison to 53 of 88 episodes (60%)
in the virus negative group (p=0.04). The mean symptom score
during respiratory exacerbations in the virus positive group was
7 compared to that of 6 for the virus negative group, though the
difference was not significant. There was no difference in theproportion of patients using peak expiratory flow reduction or
using subjective evaluation to define an exacerbation between
the two groups.
There was a significantly higher proportion of patients in the
virus positive group complaining of upper respiratory tract symp-
toms such as a runny nose (77% versus 38%, p-value=0.0003)
and sore throat (62% versus 38%, p-value=0.03) during
exacerbations. The frequencies in lower respiratory tract
complaints were similar between the two groups.
A subgroup analysis was performed comparing the samples
that were positive for either influenza A, influenza B or both and
the group that was positive for other viral infections. Of the 50
virus positive exacerbation samples (accounting for 63
respiratory viruses detected), 18 (36%) were positive for
influenza A, B or both. 4 of the 18 samples were excluded
from analysis because they also had other respiratory viruses
identified in addition to influenza virus. One of the 14
remaining samples contained both influenza A and B viruses.
32 samples (64%) were positive for other respiratory viruses
only. The reasons used to report respiratory exacerbations were
similar between the influenza and other viral groups. Summated
symptom score was the major reason used to define respiratory
exacerbations in both groups (79% in the influenza group and
81% in the other viral group). However, there were significantly
more upper respiratory symptom complaints including runny
nose (p-value=0.02), blocked nose (p-value=0.01), sore throat
(p-value=0.01), hoarse voice (p-value=0.0002) and fever/
shivery episodes (p-value=0.0002) in the influenza group
compare to the other viral group. There was no difference in the
lower respiratory symptom complaints between the groups.
3.4. Relationship between bacteria and respiratory viruses
There were 274 paired sputum samples/cough swabs
analysed for bacterial isolation (138 exacerbation and 136
routine), consisting of 84 (31%) cough swabs and 190 (69%)
sputum samples. 69 of 274 specimens (25%) were positive for
bacteria accounting for a total of 86 isolates. 8 of 84 (10%)
cough swab specimens were positive and 61 of 190 sputum
samples (32%) were positive. P. aeruginosa and S. aureus were
the major bacteria isolated accounting for 54% and 23% of all
bacteria identified, respectively.
Of the 74 nasal swabs (exacerbation and routine samples)
that were positive for at least one respiratory virus, 19 (26%) of
the paired sputum/cough swab samples were positive for
bacteria. Similarly, there were 200 nasal swab samples with no
viruses identified, 50 (25%) of them were positive for bacteria.
Hence there was no statistical difference between the viral and
non-viral groups in terms of bacteria isolation (p=0.909). There
was also no difference in Pseudomonas isolation between the
viral and non-viral groups.
When nasal swab samples were considered in terms of
routine/asymptomatic (n=136) and exacerbation (n=138)
collections, once again no difference was found between the
two groups in terms of bacterial infection status (p=0.728).
Bacteria were found in 33 (24.3%) routine samples and 36
(26.1%) exacerbation samples.
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This is a novel study using ‘real-time’ NASBA to examine
the role of respiratory viruses in CF. It has achieved the highest
detection rate of 46% amongst all existing literature concerning
respiratory viruses in the CF population during reported
episodes of respiratory illness. Our results compare favourably
with previous studies and this may be that earlier studies relied
heavily on repeated serological testing, either alone [11] or in
combination with viral isolation [4,6,7,12,26]. These traditional
methods are relatively insensitive and may have underestimated
the prevalence of viruses in CF.
We have also achieved a viral detection rate of 18.3% from
routine nasal samples and this is comparable to the seroconver-
sion rate of 12.3% as reported by Wang et al. [7]. This value is
also similar to the seroconversion rate of 16.2% from
asymptomatic samples achieved by Ramsey et al. [6]. Amongst
stable asthmatic children, Johnston et al. [25] found a viral
detection rate of 12% by PCR. Therefore, a laboratory method
with a higher sensitivity for viral detection used in this study has
not increased the detection rate in asymptomatic samples,
implying that the high detection rate in exacerbation samples is
unlikely to be due to false positive results.
PIV 4 has been reported as a cause of severe respiratory
infections in previously healthy children and can lead to an
increased risk of hospital admission [27,28] To our knowledge,
this is the first study showing that PIV4 can be detectable in CF.
The lack of data regarding PIV4 in CF may be that it was not
actively sought in previous studies and may also be due to the
lack of knowledge of this virus. This study shows that PIV4 can
be isolated in CF and could lead to pulmonary exacerbation but
further studies will be required to fully define the exact role of
PIV 4 in CF exacerbations.
This study demonstrates that influenza A and B viruses are
major viruses in causing respiratory exacerbations in CF and
both viruses are more commonly detected during pulmonary
exacerbations. 22 of 88 (23%) viruses found in this study are
influenza viruses (A and B). This figure is consistent with
majority of the previous studies which showed that influenza
virus represented between 12 to 27% of all viruses detected. In
relation to influenza vaccination, the uptake rate was up to 70%
during the 2003/4 season [24] (but we did not have the data for
our study population during 2002/2003) and the significance is
that the influenza detection rate in our study could easily have
been higher had the vaccination uptake not been this high.
Previous studies have shown that RSV were also important
viruses in CF exacerbations [4,10] and represented 9 to 58% of
all viruses in CF with the highest incidence in young children.
In our study, only 7 of 88 (8%) reported viruses were RSV and
this low detection rate may be due to nasal swabs used for
sample collection having a 20 to 30% lower detection rate than
nasopharyngeal aspirate for RSV [29]. RSV is a relatively labile
virus and the amount of virus in a small-volume nasal swab
specimen may be a lot less than that in a sample obtained by
aspiration. In addition, RSV more commonly infects the lower
airways and sampling from the upper airways by nasal swabs
could have underestimated its true prevalence [30].The 2002/03 season [31] between October 2002 and May
2003, was a high season for RSV but our study started in
December 2003 and could have potentially missed 2 months’
worth of valuable specimens. Lastly, 90% of the RSV infections
reported were amongst children between the ages of 0 to 4 years
[31] so the median age of 9 years in the study population may
account for the low RSV detection rate.
However, following a review of the case histories of the
volunteers, there were 53 occasions where respiratory exacer-
bations and diminished peak flows that were not reported.
Therefore, the total number of cases of respiratory exacerbation
was 218 over 17 months, giving an exacerbation rate per patient
per year of 2.05 and this was comparable to that reported by
previous studies [5–7,12,13,16,26,32,33].
It has been more than 20 years since Wang et al. [7] described
the relationship between respiratory viral infections and the
deterioration in clinical status in CF. Viruses were identified
through repeated serology and nasal lavage for viral isolation in
49 patients with CF (mean age 13.7 years) over 2 years.
Although the CF patients had more respiratory illnesses than
sibling controls (3.7 versus 1.7/year), there were no differences
in virus identification rates (1.7/year). All their viruses were
identified by seroconversions; none were detected by viral
cultures. From a total of 1028 (689 acute episodes versus 339
asymptomatic episodes) serum samples, 105 infections (10.2%)
were identified. 42 of the 105 infections were identified from
asymptomatic periods. Therefore their viral detection rates were
9.1% during acute episodes and 12.3% during asymptomatic
episodes, compared to our detection rates of 46% and 18.4%,
respectively. Our study also show that rhinoviruses played a
major role in exacerbations of CF but in contrast, Wang et al. [7]
failed to detect any rhinoviruses. The authors concluded that the
high serotypes of rhinoviruses making detection by serology
and cultures impossible.
Ramsey et al. [6] prospectively compared the incidence and
effect of viral infections on pulmonary function and clinical
scores in 15 schoolchildren with CF aged 5–22 years and their
unaffected siblings. Over a 2-year period, oropharyngeal
cultures and serological tests were taken at regular two monthly
intervals and during acute exacerbations for respiratory viruses.
A total of 68 acute respiratory illness (ARI) episodes occurred
in the patients with CF and in 19 episodes there was an
associated virus identified. This gave a viral detection rate of
27.9% during CF exacerbations and a rate of 27.8% when
asymptomatic. They were unable to demonstrate any significant
adverse effect of viral infections on lung functions in patients
with CF. However, they found that patients with CF had more
frequent viral infections and infections were associated with a
significantly slower rate of clinical decline. The authors also
suggested that viral infections may possibly protect against
Pseudomonas acquisition.
Rhinovirus has been found to be a major virus in CF
exacerbation in this study. Todate only 3 studies have prospectively
usedmolecular basedmethods to identify viral agents [5,12,15,16].
Over a 1-year period, Smyth et al. [15] prospectively investigated
108 patients with CF (mean age of 7.9 years) using a combination
of viral culture and immunofluoresence, seroconversion (fourfold
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During the study, 76 subjects had 157 reported respiratory
exacerbations (1.5 episodes/patient/year compared to 2.05 in
our study), and a viral agent was identified in 44 episodes
(28%) (with rhinovirus in 25 [15.9%]), and an equal
distribution of other viruses identified almost always on
seroconversion. They also found that those children in whom
a non-rhinovirus was identified had a significantly greater
decline in FEV1, whereas patients with rhinovirus infection
had fewer declines.
Collinson et al. [5] followed 48 children with CF over a
15 month period using a combination of viral culture and PCR
for picornaviruses alone. Thirty eight children completed the
study and there were 147 symptomatic upper respiratory
infections (2.7 episodes/child/year), with samples available for
119 episodes. Picornaviruses were identified in 51 (43%) of
these episodes, of which 21 (18%) were rhinoviruses. This
study confirmed the importance of this virus in CF exacerbation
similar to our findings (15.9%) from exacerbation episodes.
There are significantly more patients in the virus positive
group using the summated symptom score to define respiratory
exacerbations compared to the virus negative group, possibly
because the virus positive group had a higher perception and
awareness of increased respiratory symptoms. This suggests
that patients with more upper respiratory symptoms were more
likely to have a virus isolated from nasal swabs.
The difference in symptomology is even more striking when
the patients were divided into subgroups of influenza positives
and other viral positives. The influenza subgroup had
significantly more upper respiratory tract symptoms during
respiratory exacerbations compared to the other virus group, but
there was no difference in terms of lower respiratory
complaints. This is an important observation as this confirmed
that influenza is more likely to infect the upper airways. In
addition, we have recently shown that influenza vaccination
does offer protection against its subsequent acquisition in
patients with CF [24] contradictory to a recent Cochrane review
[34]. The recent development of intranasal vaccination may be
an effective and attractive option as this will offer local
protection in the upper airways, which can help arresting
infection at an early phase before symptom complications arise.
The data available for the optimal method for respiratory
viral detection is limited. The best sites to collect material for
viral detection may differ for different viruses, such as using
bronchoalveolar lavage (BAL) to obtain lower airways speci-
mens for RSV [30] and nasal swabs for upper airways sampling
for rhinovirus and influenza virus [29]. The collection of a nasal
swab is simple, convenient, relatively painless, does not require
any additional devices such as an electrical suction device for
obtaining nasopharyngeal aspirates (NPA) or any specialised
skill. Thus far there is no data comparing the sensitivities and
specificities of different sampling techniques incorporating
molecular detection methods for viral detection.
In future studies, it may be worth obtaining specimens from
different respiratory sites using different sampling methods
simultaneously as this may increase the diagnostic yield [35,36]
and further establish the impact of respiratory virus in CF.The bacterial isolation rate in this study was low at 25% (69
positive samples from 274), compared to a study by Olesen
et al. [17] who achieved a bacterial detection rate of 76%. This
may be that 30% of the samples obtained for bacterial isolation
in this study were cough swabs whereas Olesen et al. used a
combination of laryngeal aspirate (20%) and sputum sample
(80%) for isolation, which tended to have a higher isolation rate.
In the Brompton study [37], cough swabs had a specificity of
100% compared to sputum samples for bacteria isolation but a
sensitivity of only 34%. Another study conducted by Maiya
et al. [38] showed a similar sensitivity of 35% with cough swabs
compared to sputum samples and cough plates.
Bronchoalveolar lavage or laryngeal aspirate may be super-
ior [39,40], but these procedures carry higher risks, costs and
require more expertise and these considerations must be taken
into account before utilising these procedures for routine
screening and research purposes.
In this study, there is no change in incidence of bacterial
infection during viral infections. Symptomatic viral infections
did not increase the likelihood of bacterial infection. Therefore,
the criteria used in this study to define a respiratory
exacerbation are poor predictors of bacterial infection. The
introduction of additional antibiotics in these situations may be
difficult to decide. In addition, Ramsey et al. [6] have shown
that CF patients colonised with S. aureus did not have an
increased risk of viral infection and those colonised with
P. aeruginosa were protected from viral infections. Hence, the
high proportion of S. aureus and P. aeruginosa found in this
study may part explain the lack of association between viruses
and bacteria.
NASBA used in this study for viral identification offers
several advantages. Firstly, it is developed specifically for RNA
target amplification and is particularly suited for the detection of
RNA viruses because there is no need for a separate reverse
transcription step, unlike PCR. Secondly, the selection criteria
for NASBA primers are less stringent, allowing easier primer
design in selected less-conserved regions of the gene [41].
Thirdly, it is a continuous isothermic process that does not
require a thermocycler [42,43]. Hence a constant temperature
throughout the amplification reaction allows NASBA to
amplify the targeted RNA or DNA exponentially at each step
of the reaction. The NASBA reaction is also more efficient than
PCR methods that are restricted to binary increases per cycle.
Fourthly, background DNA does not interfere with the NASBA
reaction, as single-stranded RNA sequences are specifically
targeted, unlike PCR where background DNA may cause false
positive results [44]. The closed-tube format of NASBA assay
greatly reduces the risk of contamination and thus of false
positive results. Finally, the detection of PCR products requires
gel electrophoresis, which necessitates the transfer of resolved
nucleic acid to an agarose gel. This is very labour intensive and
time-consuming and is not as well suited for diagnostic use
compares to ‘real-time’ NASBA.
We did not study the differences in hospitalisation rates
between the viral and non-viral group as patients could have
been admitted to hospital for non-respiratory reasons as this was
not deemed as a robust end-point. Similarly, we did not study
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viral groups as one of the end-points of the study because it was
felt that antibiotics were sometimes administered for reasons
other than for pulmonary exacerbations, such as before holidays
or school examinations in order to improve lung functions and
respiratory reserve.
We did not have the assay identifying human metapneumo-
virus (hMPV), a virus that has recently been reported and it is
closely related taxonomically to RSV [45]. This virus possibly
accounts for about 10% of unexplained respiratory infections in
children during the winter season. Garcia et al [46] has recently
shown that this virus behaves similarly to RSV in CF in that it
leads to an increased risk of hospitalisation and exacerbation.
5. Conclusions
Our results provide evidence to support respiratory viruses
are commonly found during respiratory exacerbations of CF,
particularly influenza A, influenza B and rhinovirus. PIV 4 has
been detected for the first time in the CF population but its exact
role will need to be further defined. However, there is little
evidence to suggest that viral infections predispose to bacterial
infections, contrary to previous reports.
As the role of respiratory viruses in CF becomes a more
prominent entity , ‘real-time’NASBA in viral detection may play
a pivotal role in the future management of CF because of its rapid
turn-around of results. It may provide guidance to clinicians
regarding anti-viral administration, thus avoiding the inappropri-
ate use of antibiotics and further support the importance of patient
segregation. At the moment, NASBA largely remains as a
research tool and for now, clinicians will have to use a matter of
judgement and clinical accruement to diagnose viral infection as
many currently available diagnostic tools still take days or weeks
to provide definitive results. Hopefully, one day NASBA may
become widely available to allow respiratory viral testing to
become part of the routine investigation during pulmonary
exacerbations of CF. In addition, NASBA may also become a
very important screening tool for exacerbations in other
respiratory illnesses such as chronic obstructive pulmonary
disease, asthma and bronchiectasis.
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